AR086660A1 - Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada - Google Patents
Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongadaInfo
- Publication number
- AR086660A1 AR086660A1 ARP120101962A ARP120101962A AR086660A1 AR 086660 A1 AR086660 A1 AR 086660A1 AR P120101962 A ARP120101962 A AR P120101962A AR P120101962 A ARP120101962 A AR P120101962A AR 086660 A1 AR086660 A1 AR 086660A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- insulinotropic peptide
- prolonged action
- long
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica para la prevención o el tratamiento de la diabetes, caracterizada porque comprende un conjugado de insulina de acción prolongada y un conjugado de un péptido insulinotrópico de acción prolongada, en donde cada uno entre el conjugado de insulina de acción prolongada y el conjugado de un péptido insulinotrópico de acción prolongada se prepara uniendo insulina o un péptido insulinotrópico con una región Fc de inmunoglobulina por medio de un conector no peptidílico seleccionado del grupo que consiste de polietilenglicol, polipropilenglicol, copolímero de etilenglicolpropilenglicol, poliol polioxietilado, alcohol polivinílico, polisacárido, dextrano, poliviniletil éter, un polímero biodegradable, un polímero de lípidos, quitina, ácido hialurónico y una combinación de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110053488 | 2011-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086660A1 true AR086660A1 (es) | 2014-01-15 |
Family
ID=47260121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101962A AR086660A1 (es) | 2011-06-02 | 2012-06-01 | Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada |
Country Status (20)
Country | Link |
---|---|
US (2) | US10251957B2 (es) |
EP (1) | EP2717918B1 (es) |
JP (2) | JP6320293B2 (es) |
KR (1) | KR101424550B1 (es) |
CN (2) | CN109999180A (es) |
AR (1) | AR086660A1 (es) |
AU (2) | AU2012263098B2 (es) |
BR (2) | BR112013031033A2 (es) |
CA (1) | CA2837856C (es) |
CL (1) | CL2013003454A1 (es) |
IL (1) | IL229726A (es) |
MX (2) | MX362914B (es) |
MY (1) | MY187652A (es) |
PE (2) | PE20181079A1 (es) |
RU (1) | RU2606840C2 (es) |
SG (1) | SG195193A1 (es) |
TW (1) | TWI560198B (es) |
UA (1) | UA113626C2 (es) |
WO (1) | WO2012165915A2 (es) |
ZA (1) | ZA201308811B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP2016503771A (ja) | 2012-12-21 | 2016-02-08 | サノフイ | エキセンジン−4誘導体 |
KR20140088837A (ko) * | 2013-01-03 | 2014-07-11 | 한미약품 주식회사 | N-말단 전하가 변형된 인슐린 분비 펩티드 유도체 |
CA2899418C (en) * | 2013-02-26 | 2022-05-03 | Hanmi Pharm. Co., Ltd. | Site-specific insulin conjugate |
TWI755579B (zh) * | 2013-02-26 | 2022-02-21 | 南韓商韓美藥品股份有限公司 | 新穎胰島素類似物及其用途 |
AU2014241743B2 (en) * | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
AR096891A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
AR096890A1 (es) * | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
MA43289B1 (fr) | 2014-01-20 | 2019-12-31 | Hanmi Pharm Ind Co Ltd | Insuline à action prolongée et utilisation associée |
CN117065044A (zh) * | 2014-03-31 | 2023-11-17 | 韩美药品株式会社 | 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
TWI684458B (zh) * | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
US9932381B2 (en) * | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US20170209544A1 (en) * | 2014-07-15 | 2017-07-27 | The Regents Of The University Of California | A peptide therapy to counteract insulin resistance and type 2 diabetes |
TWI772252B (zh) * | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
US20160151511A1 (en) * | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
CN114366802A (zh) * | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
EA038544B1 (ru) * | 2015-12-31 | 2021-09-13 | Ханми Фарм. Ко., Лтд. | Тройной агонист рецепторов глюкагона/glp-1/gip |
WO2017160669A1 (en) * | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
TWI774694B (zh) | 2016-09-23 | 2022-08-21 | 南韓商韓美藥品股份有限公司 | 具有降低對胰島素受體之親和力之胰島素類似物及其用途 |
WO2018057977A1 (en) * | 2016-09-23 | 2018-03-29 | Delpor, Inc. | Stable compositions for incretin mimetic compounds |
AU2018215840A1 (en) * | 2017-02-03 | 2019-08-01 | Hanmi Pharm. Co., Ltd. | Long-Acting Conjugate Of A Physiologically Active Material And Use Thereof |
WO2018174668A2 (ko) | 2017-03-23 | 2018-09-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 |
US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
US20210214412A1 (en) * | 2018-04-16 | 2021-07-15 | University Of Utah Research Foundation | Glucose-responsive insulin |
US11566059B2 (en) | 2018-08-08 | 2023-01-31 | Daewoong Pharmaceutical Co., Ltd. | Long-acting insulin analogues and derivatives thereof |
KR102646845B1 (ko) * | 2018-08-08 | 2024-03-14 | 주식회사 대웅제약 | 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법 |
CN114945587A (zh) * | 2019-07-18 | 2022-08-26 | 韩美药品株式会社 | 通过制备中间体而制备长效药物缀合物的新方法 |
WO2021142733A1 (en) * | 2020-01-16 | 2021-07-22 | Shanghai Benemae Pharmaceutical Corporation | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
EA003944B1 (ru) * | 1998-02-23 | 2003-10-30 | Ньюрокрайн Байосайенсиз Инк. | Способы лечения диабета с помощью пептидных аналогов инсулина |
CA2452044A1 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
MXPA04003569A (es) * | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
AU2004282984B2 (en) | 2003-11-13 | 2011-07-14 | Hanmi Science Co., Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
WO2006029634A2 (en) | 2004-09-17 | 2006-03-23 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
KR100754667B1 (ko) * | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
EP1890722A2 (en) | 2005-05-27 | 2008-02-27 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
US8759290B2 (en) | 2005-10-18 | 2014-06-24 | Biocon Limited | Oral glucagon-like peptide conjugates for metabolic diseases |
EP1960414A4 (en) | 2005-12-08 | 2008-12-17 | Pfizer | METHOD FOR DEMETHYLATING THE 3-DIMETHYLAMINOGRUPPE OF ERYTHROMYCIN COMPOUNDS |
KR20080001479A (ko) | 2006-06-29 | 2008-01-03 | 주식회사 하이닉스반도체 | 포토 마스크의 제조 방법 및 이의 레지스트 반응 생성물제거 장치 |
US8900555B2 (en) * | 2006-07-27 | 2014-12-02 | Nektar Therapeutics | Insulin derivative formulations for pulmonary delivery |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
PL2597103T3 (pl) * | 2007-11-16 | 2017-04-28 | Novo Nordisk A/S | Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec |
CA2711749A1 (en) * | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Novel insulin derivatives having an extremely delayed time-action profile |
NZ586589A (en) * | 2008-01-09 | 2012-04-27 | Sanofi Aventis Deutschland | Novel insulin analogues having an extremely delayed time-action profile |
CN102231981A (zh) * | 2008-02-08 | 2011-11-02 | 昌达生物科技公司 | 蛋白质或肽的缓释给药组合物 |
KR20100132535A (ko) * | 2008-03-31 | 2010-12-17 | 글락소 그룹 리미티드 | 약물 융합체 및 컨주게이트 |
EA019203B9 (ru) * | 2008-06-17 | 2014-03-31 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты глюкагонового рецептора/glp-1-рецептора |
MY151184A (en) | 2008-07-23 | 2014-04-30 | Hanmi Science Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
CN102245642A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | Glp-1激动剂的结合物及其用途 |
LT2349324T (lt) * | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
KR101035811B1 (ko) | 2008-10-28 | 2011-05-20 | 현대제철 주식회사 | 프레스 경화 공정용 강판 이송 장치 |
JP2010118268A (ja) | 2008-11-13 | 2010-05-27 | Kyocera Elco Corp | コネクタ |
EA200900123A1 (ru) | 2008-11-13 | 2010-06-30 | Государственное Научное Учреждение "Физико-Технический Институт Национальной Академии Наук Беларуси" | Способ изготовления осесимметричных деталей с поверхностными слоями |
CN102256992B (zh) * | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
EP2395988A2 (en) | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
EP2395983B1 (en) | 2009-02-13 | 2020-04-08 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
KR101036010B1 (ko) | 2009-09-18 | 2011-05-23 | 삼성전기주식회사 | 카메라 모듈 |
ES2534191T3 (es) | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
KR101324828B1 (ko) | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
CN102971005A (zh) | 2010-06-24 | 2013-03-13 | 贝林格尔.英格海姆国际有限公司 | 糖尿病治疗 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
MY181626A (en) | 2013-04-03 | 2020-12-29 | Sanofi Sa | Treatment of diabetes mellitus by long-acting formulations of insulins |
-
2012
- 2012-01-06 UA UAA201313707A patent/UA113626C2/uk unknown
- 2012-06-01 KR KR1020120059464A patent/KR101424550B1/ko active IP Right Grant
- 2012-06-01 CN CN201910108563.5A patent/CN109999180A/zh active Pending
- 2012-06-01 MY MYPI2013004228A patent/MY187652A/en unknown
- 2012-06-01 MX MX2013014029A patent/MX362914B/es active IP Right Grant
- 2012-06-01 BR BR112013031033A patent/BR112013031033A2/pt not_active Application Discontinuation
- 2012-06-01 AR ARP120101962A patent/AR086660A1/es not_active Application Discontinuation
- 2012-06-01 WO PCT/KR2012/004367 patent/WO2012165915A2/en active Application Filing
- 2012-06-01 PE PE2018000412A patent/PE20181079A1/es unknown
- 2012-06-01 SG SG2013087903A patent/SG195193A1/en unknown
- 2012-06-01 RU RU2013152335A patent/RU2606840C2/ru active
- 2012-06-01 BR BR112013030977A patent/BR112013030977A2/pt not_active IP Right Cessation
- 2012-06-01 PE PE2013002729A patent/PE20140795A1/es not_active Application Discontinuation
- 2012-06-01 EP EP12792243.3A patent/EP2717918B1/en active Active
- 2012-06-01 JP JP2014513450A patent/JP6320293B2/ja active Active
- 2012-06-01 US US14/123,355 patent/US10251957B2/en active Active
- 2012-06-01 TW TW101119709A patent/TWI560198B/zh not_active IP Right Cessation
- 2012-06-01 AU AU2012263098A patent/AU2012263098B2/en not_active Ceased
- 2012-06-01 CN CN201280026982.0A patent/CN103596595A/zh active Pending
- 2012-06-01 CA CA2837856A patent/CA2837856C/en not_active Expired - Fee Related
-
2013
- 2013-11-25 ZA ZA2013/08811A patent/ZA201308811B/en unknown
- 2013-11-28 MX MX2018006844A patent/MX2018006844A/es unknown
- 2013-11-28 IL IL229726A patent/IL229726A/en active IP Right Grant
- 2013-12-02 CL CL2013003454A patent/CL2013003454A1/es unknown
-
2016
- 2016-12-09 JP JP2016239539A patent/JP2017078078A/ja active Pending
-
2017
- 2017-06-27 AU AU2017204344A patent/AU2017204344A1/en not_active Abandoned
-
2018
- 2018-11-30 US US16/206,365 patent/US20190083579A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086660A1 (es) | Composicion para el tratamiento de diabetes que comprende un conjugado de insulina de accion prolongada y conjugado de un peptido insulinotropico de accion prolongada | |
ES2651007T3 (es) | Formulación de interferón beta de acción prolongada que usa un fragmento de inmunoglobulina | |
AR090287A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de la enfermedad del higado graso no alcoholico | |
AR081066A1 (es) | Conjugado de insulina donde se usa un fragmento de inmunoglobulina | |
CY1120270T1 (el) | ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΕΧΕΙ desPro-36Εξενδίνη-4(1-39)-Lys6-NH2 ΚΑΙ ΜΕΘΕΙΟΝΙΝΗ | |
CY1119829T1 (el) | Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου | |
BRPI1007466A2 (pt) | conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba | |
CO2019003182A2 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
CL2016001809A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15). | |
CY1116163T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη, και μεθειονινη | |
BR112013007286A2 (pt) | composição polimérica, película e bolsa de autoclave. | |
AR083568A1 (es) | FORMULACIONES LIQUIDAS DE CONJUGADO DE a INTERFERON DE ACCION PROLONGADA | |
UY36186A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
BR112013023015A2 (pt) | conjungado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina. | |
NZ630888A (en) | Antibody drug conjugate (adc) purification | |
EA033537B1 (ru) | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью | |
CA2902372C (en) | Polymer conjugate for delivery of a bioactive agent | |
MX363844B (es) | Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional. | |
BR112013019628A2 (pt) | conjugados de polímero-carboidrato-lipídeo | |
NO20083573L (no) | Amfifile polymerer for opploseliggjoring og malrettet avgivelse av legemidler | |
WO2013067199A3 (en) | Subcutaneous delivery of polymer conjugates of therapeutic agents | |
CL2012003039A1 (es) | Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. | |
EA201890436A1 (ru) | Жидкая полимерная система доставки для длительного введения лекарственных средств | |
EP3006050A4 (en) | Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |